SAN DIEGO, May 31, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon and certain of Organon’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, ...

诉讼背景 - 领先证券律师事务所Bleichmar Fonti & Auld LLP宣布对Organon & Co及其部分高管提起集体诉讼 指控其违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)和20(a)条款 代表在特定期间购买公司证券的投资者 [2] - 案件由美国新泽西地区法院受理 案号Hauser v Organon & Co 25-cv-05322 [2] 指控核心内容 - 公司2024年10月完成12亿美元收购生物制药公司Dermavant后 债务水平上升但仍向投资者保证维持股息政策 [3] - 实际资本配置优先级已转向降债 最终导致股息从每股028美元大幅削减至002美元 [3][4] - 管理层在2025年5月1日声明中承认将加速去杠杆化作为首要任务 股东回报优先级降低 [4] 市场影响 - 股息削减公告导致股价单日暴跌27% 从2025年4月30日的1293美元/股跌至5月1日的945美元/股 [4] 公司业务概况 - Organon为全球女性健康领域医疗保健公司 历史上以稳定股息回报股东 [3] - 通过收购Dermavant拓展皮肤病治疗领域业务线 [3] 律所背景 - 原告律所BFA在2023年被ISS SCAS评为全美前五大原告律所 曾为特斯拉案追回9亿美元 为Teva制药案追回42亿美元 [6][7]

诉讼案件 - Organon & Co面临证券集体诉讼，指控其在2024年10月31日至2025年4月30日期间未披露重大信息，违反联邦证券法 [1][3] - 诉讼案件名称为Hauser V Organon & Co，案件编号25-cv-05322，由美国新泽西地区法院受理 [1][5] 公司财务变动 - 2025年3月10日盘前，公司公布2025年第一季度财报，宣布将季度股息从每股0.28美元大幅下调至0.02美元 [4] - 此次股息调整与公司此前承诺的"优先保障定期股息"及"资本配置策略"相矛盾 [4] - 消息公布后，股价从2025年4月30日收盘价12.93美元/股暴跌27%，至2025年5月1日的9.45美元/股 [4] 投资者参与 - 投资者需在2025年7月22日前提交首席原告申请以参与诉讼 [1] - ClaimsFiler提供免费服务协助投资者获取诉讼信息及提交索赔，包括案件注册、投资组合数据匹配及法律咨询 [6][7]

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Organon securities between October 31, 2024, to April 30, 2025, both dates inclusive (the “Class Period”). Investors have until Jul ...

集体诉讼事件 - Organon & Co (NYSE: OGN) 因涉嫌在2024年10月31日至2025年4月30日期间误导投资者面临集体诉讼 [1] - 诉讼由Robbins LLP发起 主要针对公司债务削减策略的信息披露问题 [2] 指控内容 - 公司被指控在强调季度分红为"资本配置第一优先级"的同时 隐瞒收购Dermavant后债务削减策略的实际优先级 [2][3] - 2025年5月1日公司宣布将季度股息从每股0.28美元大幅削减至0.02美元 降幅达70% [3][4] 市场影响 - 股息调整公告导致公司股价从2025年4月30日的12.93美元/股暴跌至5月1日的9.45美元/股 单日跌幅超27% [4] 公司背景 - Organon & Co为全球医疗保健公司 专注于女性全生命周期健康管理 [1] - 公司近期完成对Dermavant的收购 该交易可能影响其资本配置策略 [3] 法律程序 - Robbins LLP自2002年起专注股东权益诉讼 本次采用风险代理收费模式 [6] - 投资者可选择作为首席原告或保持缺席集体成员身份 [5]

NEW YORK, May 30, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2025.So what: If you purchased Organon securities during the Class Period you may ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Organon & Co. (NYSE: OGN) in the United States District Court for the District of New Jersey. Investors who acquired Organon shares during the class period are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Class Action Details Defendant: Or ...

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between October 31, 2024 through April 30, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff representat ...

NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid= ...

集体诉讼案件 - 罗森律师事务所宣布代表在2024年10月31日至2025年4月30日期间购买Organon证券的投资者提起集体诉讼 [1] - 诉讼指控被告在向投资者提供过于积极陈述的同时 传播了重大虚假和误导性声明 并隐瞒了与资本配置相关的重大不利事实 [5] - 被告隐瞒了收购Dermavant后公司债务削减策略的高优先级 导致季度股息减少70% [5] 律师事务所背景 - 罗森律师事务所专注于证券集体诉讼和股东衍生诉讼 在全球范围内代表投资者 [4] - 该律所曾创下针对中国公司的最大证券集体诉讼和解记录 [4] - 2017年被ISS证券集体诉讼服务评为和解数量第一 2013年以来每年排名前四 [4] - 2019年为投资者追回超过4.38亿美元 累计为投资者追回数亿美元 [4] 投资者参与方式 - 投资者可在2025年7月22日前申请担任首席原告 [1][3] - 参与方式包括访问特定网址或联系Phillip Kim律师 [3][6] - 投资者可选择保留自己的律师或保持缺席成员身份 [7]